Menu

Merck Buys Sigma-Aldrich for $17B

Two giants merge as the German drug maker acquires the US-based science supply company.

Sep 22, 2014
Kerry Grens

WIKIMEDIA, GERIBETH CIULLOThe German pharmaceutical and chemical company Merck is purchasing Sigma-Aldrich, which supplies a wide swath of lab reagents, for a whopping $17 billion. According to Reuters, the deal contributes to a record-breaking year for transactions in the healthcare industry, “with year-to-date activity in the sector topping $380 billion, well over double the year-ago level, according to Thomson Reuters data.”

Merck has been growing its lab supply side to become one of the biggest companies in the business, having bought EMD Millipore (a.k.a. Merck Millipore), which sells reagents and lab tools, in 2010. “Sigma helps fill in a lot of the missing pieces” for Merck, Ross Muken, a life sciences industry analyst with ISI Group LLC in New York, told The Wall Street Journal. Merck will now sell the range of life science products, from basic science tools and reagents to pharmaceuticals.

According to the Associated Press, Merck CEO Karl-Ludwig Kley said the firm had a “clear commitment” to St. Louis, Missouri, where Sigma-Aldrich is based. According to the news report, “he said it was too early in the integration process to answer a question about possible job losses at any of the company’s facilities.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!